HCP1803-3

DRUG5 trials

Sponsors

Hanmi Pharmaceutical Company Limited

Conditions

HealthyHypertension

Phase 1

A Study to Evaluate the PK, Safety and Tolerability of HCP1803.

CompletedNCT05723549

Hanmi Pharmaceutical Company LimitedHealthy

Start: 2023-02-02End: 2023-03-20Updated: 2023-09-22

Phase 2

A Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential Hypertension

CompletedNCT04959305

Hanmi Pharmaceutical Company LimitedHypertension

Start: 2021-04-22End: 2022-02-28Updated: 2022-07-14

Phase 3

A Study to Evaluate Efficacy and Safety of HCP1803 in Patients With Essential Hypertension

CompletedNCT05362110

Hanmi Pharmaceutical Company LimitedHypertension

Start: 2022-05-16End: 2023-06-05Updated: 2023-09-26

A Study to Evaluate Efficacy and Safety of HCP1803 Compared to RLD2001-1 in Patients with Essential Hypertension

CompletedNCT06438172

Hanmi Pharmaceutical Company LimitedHypertension

Start: 2024-03-25End: 2024-12-02Updated: 2025-02-19

A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension

Not yet recruitingNCT07660796

Hanmi Pharmaceutical Company LimitedHypertension

Start: 2026-07-06End: 2027-11-30Target: 256Updated: 2026-06-30

Related Papers

SINGLE-PILL COMBINATION OF THIRD-DOSE TRIPLE ANTIHYPERTENSIVE THERAPY VERSUS STANDARD-DOSE MONOTHERAPY IN PATIENTS WITH MILD TO MODERATE HYPERTENSION

Journal of Hypertension2024-05-011 citations